Ziopharm Oncology Announces Exclusive License with National Cancer Institute to Identify and Use T-Cell Receptors Targeting Neoantigens for Cancer with Sleeping Beauty Platform

NEXT STORY
MacroGenics to Host Conference Call and Webcast to Review Margetuximab Phase 3 SOPHIA Study Presentation at ASCO
PREV STORY
Oncology Venture – nytt datum för registrering i den pågående företrädesemissionen
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 Test Used in DIRECT Study to Investigate the T Cell Response and COVID Vaccination in Ethnic Minority Groups

author_avatar
NASDAQ Market News

Global infectious diseases in-vitro diagnostics market size to expand at 3.8% CAGR through 2027

author_avatar
NASDAQ Market News

Dehaier Medical Systems Showcases Its Wearable Sleep Respiratory Solution at Two Premier Sleep Conferences

BEIJING, Sept. 02, 2015 (GLOBE NEWSWIRE) -- Dehaier Medical Systems Ltd. (Nasdaq:DHRM) ("Dehaier" or ...

author_avatar
NASDAQ Market News